Hansa Biopharma comment on today's Q1 report
Shares in Hansa Biopharma dropped around 12 percent today following the company’s release of its first quarter report showing revenue of SEK 24,2 million which was slightly below analysts’ estimates of SEK 27 million, suggesting Hansa Biopharma had one patient less during the quarter than the 6 patients expected by analysts. Upfront payments from partner Sarepta in gene therapy was SEK 9,9 million, once again showing a meaningful contribution to revenue.
Net cash by the end of the period was SEK 1.286,8 million, which was lower than analysts’ estimates, suggesting higher research and development activities as also indicated by higher operating and cash flow loss than expected. This is likely as Hansa Biopharma continues to broaden the scope and indication for the use of its imlifidase platform.
Highlights from the report:
- Positive reimbursement decision in Spain expands market access to include the five largest European markets
- Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed
- HNSA-5487: Phase 1 clinical study started in healthy volunteers
HC Andersen Capital will be hosting an event on Monday April 24th at 1:00 PM CET where Head Of Investor Relation Klaus Sindahl will comment on the report and take questions. Please use this link for participation: https://www.inderes.dk/videos/hansa-biopharma-presentation-of-q1-interim-report-2023
HC Andersen Capital receives payment from Hansa Biopharma for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 7:05 PM CET 04-20-2023.
Hansa Biopharma
Hansa Biopharma er en svensk biotekvirksomhed imlifidase (Idefirix) som hovedproduktet. Imlifidase er et antistof-spaltende enzym, der udvikles til at muliggøre nyretransplantation hos stærkt sensibiliserede patienter. Enzymet kan videreudvikles til brug ved andre typer transplantation, i autoimmune sygdomme, genterapi og onkologi. Hidtil er Idefirix blevet betinget godkendt i EU til højsensibiliserede nyretransplanterede patienter. I øjeblikket udfører Hansa et afgørende randomiseret kontrolforsøg i nyretransplantation i USA og forventer at påbegynde et yderligere afgørende studie på tværs af USA og EU i den sjældne autoimmune sygdom anti-GBM i løbet af 2022. Derudover fremmer Hansas forsknings- og udviklingsprogram enzymteknologien til at udvikle den næste generation af IgG-spaltende enzymer med potentielt lavere immunogenicitet, velegnet til gentagende dosering ved recidiverende autoimmune sygdomme og onkologi.
Read more on company page